Matches in SemOpenAlex for { <https://semopenalex.org/work/W3165137359> ?p ?o ?g. }
Showing items 1 to 85 of
85
with 100 items per page.
- W3165137359 endingPage "669" @default.
- W3165137359 startingPage "669.2" @default.
- W3165137359 abstract "Background: Few comparative data exist on early infections secondary to remission-induction therapy (RIT) with rituximab versus cyclophosphamide in newly-diagnosed ANCA-associated vasculitis (AAV) patients. Objectives: We compared and analyzed the rate and predictors of severe infections in such patients within the first six months following RIT. Methods: We included, from the databases of Caen University Hospital, all consecutive adults newly-diagnosed with granulomatosis with polyangiitis or microscopic polyangiitis between January 2006 and December 2019. We compared the survival without severe infections (WSI) and the survival without infection of any severity (WIOAS) within 6 months from the RIT, and used a multivariate cox analysis to identify predictors of infection. Results: We included 145 patients, 27 in rituximab group and 118 in cyclophosphamide group. Patients in the rituximab group more frequently had pneumococcal vaccination (p<0.01) and creatinine level <150 µmol/L, while other characteristics, including Birmingham Vasculitis Activity Score, were comparable between both groups. Overall, 37 severe infections and 65 infections of any severity were recorded. The survival WSI was similar in both groups (p=0.69), but survival WIOAS was lower in rituximab group (p=0.005). In multivariate analysis, risk factors at diagnosis for severe infections were chronic urinary tract disease, dialysis and absence of prophylaxis with trimethoprim-sulfamethoxazole (p<0.01 each). Conclusion: The survival WIS within the 6 months following RIT was similar in patients with newly-diagnosed AAV treated by rituximab or cyclophosphamide, but survival WIOAS appeared to be lower within the 6 months following rituximab despite a better pneumococcal vaccination coverage. Figure 1. Comparison of the 6-month survival without severe infection (A) or without infection of any severity (B) in patients with newly-diagnosed ANCA-associated vasculitis treated by rituximab or cyclophosphamide Disclosure of Interests: None declared" @default.
- W3165137359 created "2021-06-07" @default.
- W3165137359 creator A5001418994 @default.
- W3165137359 creator A5003170199 @default.
- W3165137359 creator A5006719806 @default.
- W3165137359 creator A5006955984 @default.
- W3165137359 creator A5018260007 @default.
- W3165137359 creator A5032254841 @default.
- W3165137359 creator A5032849562 @default.
- W3165137359 creator A5043026295 @default.
- W3165137359 creator A5044691942 @default.
- W3165137359 creator A5046753582 @default.
- W3165137359 creator A5055267294 @default.
- W3165137359 creator A5079701052 @default.
- W3165137359 creator A5085303269 @default.
- W3165137359 date "2021-05-19" @default.
- W3165137359 modified "2023-09-26" @default.
- W3165137359 title "POS0831 EARLY INFECTIOUS RISK IN PATIENTS WITH NEWLY-DIAGNOSED ANTI-NEUTROPHILCYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS ACCORDING TO THE REMISSION-INDUCTIONTHERAPY: A FRENCH MONOCENTRIC RETROSPECTIVE STUDY INCLUDING 145 PATIENTS" @default.
- W3165137359 doi "https://doi.org/10.1136/annrheumdis-2021-eular.3098" @default.
- W3165137359 hasPublicationYear "2021" @default.
- W3165137359 type Work @default.
- W3165137359 sameAs 3165137359 @default.
- W3165137359 citedByCount "0" @default.
- W3165137359 crossrefType "journal-article" @default.
- W3165137359 hasAuthorship W3165137359A5001418994 @default.
- W3165137359 hasAuthorship W3165137359A5003170199 @default.
- W3165137359 hasAuthorship W3165137359A5006719806 @default.
- W3165137359 hasAuthorship W3165137359A5006955984 @default.
- W3165137359 hasAuthorship W3165137359A5018260007 @default.
- W3165137359 hasAuthorship W3165137359A5032254841 @default.
- W3165137359 hasAuthorship W3165137359A5032849562 @default.
- W3165137359 hasAuthorship W3165137359A5043026295 @default.
- W3165137359 hasAuthorship W3165137359A5044691942 @default.
- W3165137359 hasAuthorship W3165137359A5046753582 @default.
- W3165137359 hasAuthorship W3165137359A5055267294 @default.
- W3165137359 hasAuthorship W3165137359A5079701052 @default.
- W3165137359 hasAuthorship W3165137359A5085303269 @default.
- W3165137359 hasBestOaLocation W31651373591 @default.
- W3165137359 hasConcept C126322002 @default.
- W3165137359 hasConcept C141071460 @default.
- W3165137359 hasConcept C167135981 @default.
- W3165137359 hasConcept C2776015282 @default.
- W3165137359 hasConcept C2776694085 @default.
- W3165137359 hasConcept C2776755627 @default.
- W3165137359 hasConcept C2778910314 @default.
- W3165137359 hasConcept C2779134260 @default.
- W3165137359 hasConcept C2779338263 @default.
- W3165137359 hasConcept C2780653079 @default.
- W3165137359 hasConcept C2781229154 @default.
- W3165137359 hasConcept C71924100 @default.
- W3165137359 hasConcept C90924648 @default.
- W3165137359 hasConceptScore W3165137359C126322002 @default.
- W3165137359 hasConceptScore W3165137359C141071460 @default.
- W3165137359 hasConceptScore W3165137359C167135981 @default.
- W3165137359 hasConceptScore W3165137359C2776015282 @default.
- W3165137359 hasConceptScore W3165137359C2776694085 @default.
- W3165137359 hasConceptScore W3165137359C2776755627 @default.
- W3165137359 hasConceptScore W3165137359C2778910314 @default.
- W3165137359 hasConceptScore W3165137359C2779134260 @default.
- W3165137359 hasConceptScore W3165137359C2779338263 @default.
- W3165137359 hasConceptScore W3165137359C2780653079 @default.
- W3165137359 hasConceptScore W3165137359C2781229154 @default.
- W3165137359 hasConceptScore W3165137359C71924100 @default.
- W3165137359 hasConceptScore W3165137359C90924648 @default.
- W3165137359 hasIssue "Suppl 1" @default.
- W3165137359 hasLocation W31651373591 @default.
- W3165137359 hasOpenAccess W3165137359 @default.
- W3165137359 hasPrimaryLocation W31651373591 @default.
- W3165137359 hasRelatedWork W1979010917 @default.
- W3165137359 hasRelatedWork W1990137326 @default.
- W3165137359 hasRelatedWork W1995250273 @default.
- W3165137359 hasRelatedWork W2005449894 @default.
- W3165137359 hasRelatedWork W2077982979 @default.
- W3165137359 hasRelatedWork W2133531497 @default.
- W3165137359 hasRelatedWork W2138672810 @default.
- W3165137359 hasRelatedWork W2331407017 @default.
- W3165137359 hasRelatedWork W2525182362 @default.
- W3165137359 hasRelatedWork W2760216409 @default.
- W3165137359 hasVolume "80" @default.
- W3165137359 isParatext "false" @default.
- W3165137359 isRetracted "false" @default.
- W3165137359 magId "3165137359" @default.
- W3165137359 workType "article" @default.